Test Bank for Lehnes Pharmacology for Nursing Care 10th Edition By Burchum

Original price was: $35.00.Current price is: $26.50.

Test Bank for Lehnes Pharmacology for Nursing Care 10th Edition By Burchum Digital Instant Download

Category:

This is completed downloadable of Test Bank for Lehnes Pharmacology for Nursing Care 10th Edition By Burchum

Product Details:

  • ISBN-10 ‏ : ‎ 0323512275
  • ISBN-13 ‏ : ‎ 978-0323512275
  • Author: Jacqueline Burchum

With a clear explanation of drug prototypes and how they work, Lehne’s Pharmacology for Nursing Care, 10th Edition gives you the background you need to understand drugs currently on the market, and those not yet released. This perennial favorite of students and teachers simplifies complex concepts while distinguishing need-to-know content from the material that’s merely nice to know. The 10th edition includes updated drug content to reflect the very latest FDA approvals, withdrawals, and therapeutic uses, as well as corresponding updated nursing content. It also includes an updated prototype drugs section, summarizing their major uses, and an updated table detailing care throughout the lifespan of the patient. Additionally, each chapter ends with a nursing implications summary to help you fully understand the material and apply it to clinical nursing practice.

  • Prototype Drugs features serve as a quick-reference learning aid so you can apply your understanding to related drugs currently on the market as well as drugs that will be released in the future.
  • UNIQUE! Engaging writing style with clear explanations makes difficult pharmacology concepts easy to grasp and even enjoyable to learn.
  • Nursing implications of drug therapy are integrated throughout the text to reinforce the integral relationship between drug therapy and nursing care.
  • UPDATED Special Interest Topic boxes focus on currently trending issues in pharmacology, eliminating out-of-date content.
  • Large print highlights essential, need-to-know information, and small print indicates nice-to-know information.
  • QSEN focus includes Patient-Centered Care Across the Life Span featureshighlighting safe and appropriate patient care during different phases of life.
  • Safety Alert features emphasize the QSEN competency relating to patient safety.
  • Student-friendly features make learning easier with concise drug summary tables, chapter outlines, key points, and a visual guide to the prototype drugs in each class.
  • Concise drug summary tables present detailed information for individual drugs, including drug class, generic and trade names, dosages, routes, and indications.
  • Selected Canadian drug names are indicated with a maple-leaf icon throughout the text.
  • Separate Bioterrorism chapter discusses the clinical manifestations and treatment of biological weapon attacks.
  • NEW! Thoroughly updated drug content reflects the very latest FDA drug approvals, withdrawals, and therapeutic uses, as well as corresponding updated nursing content
  • NEW! Additional images included to accompany difficult concepts.
  • NEW! Inclusion of more student practice questions provide additional help for learning the material.

 

Table of Content:

  1. Chapter 1 Orientation to Pharmacology
  2. Four Basic Terms
  3. Properties of an Ideal Drug
  4. The Therapeutic Objective
  5. Factors That Determine the Intensity of Drug Responses
  6. Key Points
  7. Chapter 2 Application of Pharmacology in Nursing Practice
  8. Evolution of Nursing Responsibilities Regarding Drugs
  9. Application of Pharmacology in Patient Care
  10. Application of Pharmacology in Patient Education
  11. Application of the Nursing Process in Drug Therapy
  12. Key Points
  13. Chapter 3 Drug Regulation, Development, Names, and Information
  14. Landmark Drug Legislation
  15. Hazardous Drug Exposure
  16. New Drug Development
  17. Drug Names
  18. Over-the-Counter Drugs
  19. Sources of Drug Information
  20. Key Points
  21. Unit II Basic Principles of Pharmacology
  22. Chapter 4 Pharmacokinetics
  23. Application of Pharmacokinetics in Therapeutics
  24. A Note to Chemophobes
  25. Passage of Drugs Across Membranes
  26. Absorption
  27. Distribution
  28. Metabolism
  29. Excretion
  30. Time Course of Drug Responses
  31. Key Points
  32. Chapter 5 Pharmacodynamics
  33. Dose-Response Relationships
  34. Drug-Receptor Interactions
  35. Drug Responses That Do Not Involve Receptors
  36. Interpatient Variability in Drug Responses
  37. The Therapeutic Index
  38. Key Points
  39. Chapter 6 Drug Interactions
  40. Drug-Drug Interactions
  41. Drug-Food Interactions
  42. Drug-Supplement Interactions
  43. Key Points
  44. Chapter 7 Adverse Drug Reactions and Medication Errors
  45. Adverse Drug Reactions
  46. Medication Errors
  47. Key Points
  48. Chapter 8 Individual Variation in Drug Responses
  49. Body Weight and Composition
  50. Age
  51. Pathophysiology
  52. Tolerance
  53. Placebo Effect
  54. Variability in Absorption
  55. Genetics and Pharmacogenomics
  56. Gender- and Race-Related Variations
  57. Comorbidities and Drug Interactions
  58. Diet
  59. Failure to Take Medicine as Prescribed
  60. Key Points
  61. Unit III Drug Therapy Across The Life Span
  62. Chapter 9 Drug Therapy During Pregnancy and Breast-Feeding
  63. Drug Therapy During Pregnancy: Basic Considerations
  64. Drug Therapy During Pregnancy: Teratogenesis
  65. Drug Therapy During Breast-Feeding
  66. Key Points
  67. Chapter 10 Drug Therapy in Pediatric Patients
  68. Pharmacokinetics: Neonates and Infants
  69. Pharmacokinetics: Children 1 Year and Older
  70. Adverse Drug Reactions
  71. Dosage Determination
  72. Promoting Adherence
  73. Key Points
  74. Chapter 11 Drug Therapy in Older Adults
  75. Pharmacokinetic Changes in Older Adults
  76. Pharmacodynamic Changes in Older Adults
  77. Adverse Drug Reactions and Drug Interactions
  78. Promoting Adherence
  79. Considerations for End-of-Life Care
  80. Key Points
  81. Unit IV Peripheral Nervous System Drugs
  82. Section 1 Introduction
  83. Chapter 12 Basic Principles of Neuropharmacology
  84. How Neurons Regulate Physiologic Processes
  85. Basic Mechanisms by Which Neuropharmacologic Agents Act
  86. Multiple Receptor Types and Selectivity of Drug Action
  87. An Approach to Learning About Peripheral Nervous System Drugs
  88. Key Points
  89. Chapter 13 Physiology of the Peripheral Nervous System
  90. Divisions of the Nervous System
  91. Overview of Autonomic Nervous System Functions
  92. Basic Mechanisms By Which the Autonomic Nervous System Regulates Physiologic Processes
  93. Anatomic Considerations
  94. Introduction to Transmitters of the Peripheral Nervous System
  95. Introduction to Receptors of the Peripheral Nervous System
  96. Exploring the Concept of Receptor Subtypes
  97. Locations of Receptor Subtypes
  98. Functions of Cholinergic and Adrenergic Receptor Subtypes
  99. Transmitter Life Cycles
  100. Key Points
  101. Section 2 Cholinergic Drugs
  102. Chapter 14 Muscarinic Agonists and Antagonists
  103. Introduction to Cholinergic Drugs
  104. Muscarinic Agonists and Antagonists
  105. Summary of Major Nursing Implications
  106. Chapter 15 Cholinesterase Inhibitors and Their Use in Myasthenia Gravis
  107. Reversible Cholinesterase Inhibitors
  108. Irreversible Cholinesterase Inhibitors
  109. Myasthenia Gravis
  110. Key Points
  111. Summary of Major Nursing Implications
  112. Chapter 16 Drugs That Block Nicotinic Cholinergic Transmission
  113. Control of Muscle Contraction
  114. Competitive (Nondepolarizing) Neuromuscular Blockers
  115. Depolarizing Neuromuscular Blockers: Succinylcholine
  116. Therapeutic Uses of Neuromuscular Blockers
  117. Key Points
  118. Summary of Major Nursing Implications
  119. Section 3 Adrenergic Drugs
  120. Chapter 17 Adrenergic Agonists
  121. Mechanisms of Adrenergic Receptor Activation
  122. Overview of the Adrenergic Agonists
  123. Therapeutic Applications and Adverse Effects of Adrenergic Receptor Activation
  124. Properties of Representative Adrenergic Agonists
  125. Key Points
  126. Summary of Major Nursing Implications
  127. Chapter 18 Adrenergic Antagonists
  128. Alpha-Adrenergic Antagonists
  129. Beta-Adrenergic Antagonists
  130. Summary of Major Nursing Implications
  131. Chapter 19 Indirect-Acting Antiadrenergic Agents
  132. Centrally Acting Alpha2 Agonists
  133. Adrenergic Neuron-Blocking Agents
  134. Key Points
  135. Summary of Major Nursing Implications
  136. Unit V Central Nervous System Drugs
  137. Section 4 Introduction
  138. Chapter 20 Introduction to Central Nervous System Pharmacology
  139. Transmitters of the CNS
  140. The Blood-Brain Barrier
  141. How Do CNS Drugs Produce Therapeutic Effects?
  142. Adaptation of the CNS to Prolonged Drug Exposure
  143. Development of New Psychotherapeutic Drugs
  144. Approaching the Study of CNS Drugs
  145. Key Points
  146. Section 5 Drugs for Neurodegenerative Disorders
  147. Chapter 21 Drugs for Parkinson Disease
  148. Pathophysiology That Underlies Motor Symptoms
  149. Overview of Motor Symptom Management
  150. Pharmacology of Drugs Used for Motor Symptoms
  151. Nonmotor Symptoms and Their Management
  152. Key Points
  153. Summary of Major Nursing Implications
  154. Chapter 22 Drugs for Alzheimer’s Disease
  155. Pathophysiology
  156. Risk Factors and Symptoms
  157. Drugs for Cognitive Impairment
  158. Drugs for Neuropsychiatric Symptoms
  159. Can We Prevent Alzheimer’s Disease or Delay Cognitive Decline?
  160. Key Points
  161. Chapter 23 Drugs for Multiple Sclerosis
  162. Overview of MS and Its Treatment
  163. Disease-Modifying Drugs I: Immunomodulators
  164. Disease-Modifying Drugs II: Immunosuppressants
  165. Drugs Used to Manage MS Symptoms
  166. Key Points
  167. Summary of Major Nursing Implications
  168. Section 6 Neurologic Drugs
  169. Chapter 24 Drugs for Seizure Disorders
  170. Seizure Generation
  171. Types of Seizures
  172. How Antiepileptic Drugs Work
  173. Basic Therapeutic Considerations
  174. Classification of Antiepileptic Drugs
  175. Traditional Antiepileptic Drugs
  176. Newer Antiepileptic Drugs
  177. Management of Generalized Convulsive Status Epilepticus
  178. Key Points
  179. Summary of Major Nursing Implications
  180. Chapter 25 Drugs for Muscle Spasm and Spasticity
  181. Drugs for Spasticity
  182. Drugs for Localized Muscle Spasm
  183. Other Centrally Acting Muscle Relaxants
  184. Key Points
  185. Summary of Major Nursing Implications
  186. Section 7 Drugs for Pain
  187. Chapter 26 Local Anesthetics
  188. Basic Pharmacology of Local Anesthetics
  189. Properties of Individual Local Anesthetics
  190. Clinical Use of Local Anesthetics
  191. Key Points
  192. Summary of Major Nursing Implications
  193. Chapter 27 General Anesthetics
  194. Inhalation Anesthetics
  195. Intravenous Anesthetics
  196. Summary of Major Nursing Implications
  197. Chapter 28 Opioid Analgesics, Opioid Antagonists, and Nonopioid Centrally Acting Analgesics
  198. Opioid Analgesics
  199. Opioid Antagonists
  200. Nonopioid Centrally Acting Analgesics
  201. Summary of Major Nursing Implications
  202. Chapter 29 Pain Management in Patients With Cancer
  203. Pathophysiology of Pain
  204. Management Strategy
  205. Assessment and Ongoing Evaluation
  206. Drug Therapy
  207. Nondrug Therapy
  208. Pain Management in Special Populations
  209. Patient Education
  210. The Joint Commission Pain Management Standards
  211. Key Points
  212. Chapter 30 Drugs for Headache
  213. Migraine Headache
  214. Cluster Headaches
  215. Tension-Type Headache
  216. Summary of Major Nursing Implications
  217. Section 8 Psychotherapeutic Drugs
  218. Chapter 31 Antipsychotic Agents and Their Use in Schizophrenia
  219. Schizophrenia: Clinical Presentation and Etiology
  220. First-Generation (Conventional) Antipsychotics
  221. Second-Generation (Atypical) Antipsychotics
  222. Depot Antipsychotic Preparations
  223. Management of Schizophrenia
  224. Key Points
  225. Summary of Major Nursing Implications
  226. Chapter 32 Antidepressants
  227. Major Depression: Clinical Features, Pathogenesis, and Treatment Overview
  228. Drugs Used for Depression
  229. Somatic (Nondrug) Therapies for Depression
  230. Summary of Major Nursing Implications
  231. Chapter 33 Drugs for Bipolar Disorder
  232. Characteristics of Bipolar Disorder
  233. Treatment of Bipolar Disorder
  234. Mood-Stabilizing Drugs
  235. Antipsychotic Drugs
  236. Key Points
  237. Summary of Major Nursing Implications
  238. Chapter 34 Sedative-Hypnotic Drugs
  239. Benzodiazepines
  240. Benzodiazepine-Like Drugs
  241. Ramelteon: A Melatonin Agonist
  242. Suvorexant: An Orexin Antagonist
  243. Barbiturates
  244. Management of Insomnia
  245. Key Points
  246. Summary of Major Nursing Implications
  247. Chapter 35 Management of Anxiety Disorders
  248. Generalized Anxiety Disorder
  249. Panic Disorder
  250. Obsessive-Compulsive Disorder
  251. Social Anxiety Disorder (Social Phobia)
  252. Post-Traumatic Stress Disorder
  253. Key Points
  254. Chapter 36 Central Nervous System Stimulants and Attention-Deficit/Hyperactivity Disorder
  255. Central Nervous System Stimulants
  256. Attention-Deficit/Hyperactivity Disorder
  257. Summary of Major Nursing Implications
  258. Section 9 Drug Abuse
  259. Chapter 37 Substance Use Disorders I
  260. Definitions
  261. Diagnostic Criteria Regarding Substance Use Disorder
  262. Factors That Contribute to Substance Use Disorder
  263. Neurobiology of Substance Use Disorder
  264. Principles of Substance Use Disorder Treatment
  265. The Controlled Substances Act
  266. Key Points
  267. Chapter 38 Substance Use Disorders II
  268. Basic Pharmacology of Alcohol
  269. Alcohol Use Disorder (AUD)
  270. Drugs for Alcohol Use Disorder
  271. Key Points
  272. Summary of Major Nursing Implications
  273. Chapter 39 Substance Use Disorders III
  274. Basic Pharmacology of Nicotine
  275. Pharmacologic Aids to Smoking Cessation
  276. Key Points
  277. Chapter 40 Substance Use Disorders IV
  278. Heroin, Oxycodone, and Other Opioids
  279. General CNS Depressants
  280. Psychostimulants
  281. Marijuana and Related Preparations
  282. Psychedelics
  283. Dissociative Drugs
  284. Dextromethorphan
  285. 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)
  286. Inhalants
  287. Anabolic Steroids
  288. Key Points
  289. Unit VI Drugs That Affect Fluid and Electrolyte Balance
  290. Chapter 41 Diuretics
  291. Review of Renal Anatomy and Physiology
  292. Introduction to Diuretics
  293. Loop Diuretics
  294. Thiazides and Related Diuretics
  295. Potassium-Sparing Diuretics
  296. Mannitol: an Osmotic Diuretic
  297. Key Points
  298. Summary of Major Nursing Implications
  299. Chapter 42 Agents Affecting the Volume and Ion Content of Body Fluids
  300. Disorders of Fluid Volume and Osmolality
  301. Acid-Base Disturbances
  302. Potassium Imbalances
  303. Magnesium Imbalances
  304. Key Points
  305. Unit VII Drugs That Affect the Heart, Blood Vessels, and Blood
  306. Chapter 43 Review of Hemodynamics
  307. Overview of the Circulatory System
  308. Regulation of Cardiac Output
  309. Regulation of Arterial Pressure
  310. Key Points
  311. Chapter 44 Drugs Acting on the Renin-Angiotensin-Aldosterone System
  312. Physiology of the Renin-Angiotensin-Aldosterone System
  313. Angiotensin-Converting Enzyme Inhibitors
  314. Angiotensin II Receptor Blockers
  315. Aliskiren, a Direct Renin Inhibitor
  316. Aldosterone Antagonists
  317. Key Points
  318. Summary of Major Nursing Implications
  319. Chapter 45 Calcium Channel Blockers
  320. Calcium Channels: Physiologic Functions and Consequences of Blockade
  321. Calcium Channel Blockers: Classification and Sites of Action
  322. Verapamil and Diltiazem: Agents That Act on Vascular Smooth Muscle and the Heart
  323. Dihydropyridines: Agents That Act Mainly on Vascular Smooth Muscle
  324. Key Points
  325. Summary of Major Nursing Implications
  326. Chapter 46 Vasodilators
  327. Basic Concepts in Vasodilator Pharmacology
  328. Pharmacology of Individual Vasodilators
  329. Key Points
  330. Chapter 47 Drugs for Hypertension
  331. Basic Considerations in Hypertension
  332. Management of Chronic Hypertension
  333. Drugs for Hypertensive Emergencies
  334. Drugs for Hypertensive Disorders of Pregnancy
  335. Summary of Major Nursing Implications
  336. Chapter 48 Drugs for Heart Failure
  337. Pathophysiology of Heart Failure
  338. Overview of Drugs Used to Treat Heart Failure
  339. Digoxin, a Cardiac Glycoside
  340. Management of Heart Failure
  341. Key Points
  342. Summary of Major Nursing Implications
  343. Chapter 49 Antidysrhythmic Drugs
  344. Cardiac Electrophysiology, Dysrhythmias, and the Antidysrhythmic Drugs
  345. Pharmacology of the Antidysrhythmic Drugs
  346. Summary of Major Nursing Implications
  347. Chapter 50 Prophylaxis of Atherosclerotic Cardiovascular Disease
  348. Cholesterol
  349. Plasma Lipoproteins
  350. Role of LDL Cholesterol in Atherosclerosis
  351. 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk
  352. Drugs and Other Products Used to Improve Plasma Lipid Levels
  353. Key Points
  354. Summary of Major Nursing Implications
  355. Chapter 51 Drugs for Angina Pectoris
  356. Determinants of Cardiac Oxygen Demand and Oxygen Supply
  357. Angina Pectoris: Pathophysiology and Treatment Strategy
  358. Organic Nitrates
  359. Beta Blockers
  360. Calcium Channel Blockers
  361. Ranolazine
  362. Treatment Measures
  363. Key Points
  364. Summary of Major Nursing Implications
  365. Chapter 52 Anticoagulant, Antiplatelet, and Thrombolytic Drugs
  366. Coagulation: Physiology and Pathophysiology
  367. Overview of Drugs for Thromboembolic Disorders
  368. Summary of Major Nursing Implications
  369. Chapter 53 Management of ST-Elevation Myocardial Infarction
  370. Pathophysiology of STEMI
  371. Diagnosis of STEMI
  372. Management of STEMI
  373. Complications of STEMI
  374. Secondary Prevention of STEMI
  375. Key Points
  376. Chapter 54 Drugs for Hemophilia
  377. Basic Considerations
  378. Preparations Used to Treat Hemophilia
  379. Key Points
  380. Summary of Major Nursing Implications
  381. Chapter 55 Drugs for Deficiency Anemias
  382. Red Blood Cell Development
  383. Iron Deficiency
  384. Vitamin B12 Deficiency
  385. Folic Acid Deficiency
  386. Summary of Major Nursing Implications
  387. Chapter 56 Hematopoietic Agents
  388. Hematopoietic Growth Factors
  389. Drugs That Mimic Hematopoietic Growth Factors or Enhance Their Actions
  390. Summary of Major Nursing Implications
  391. Unit VIII Drugs for Endocrine Disorders
  392. Chapter 57 Drugs for Diabetes Mellitus
  393. Diabetes Mellitus
  394. Insulin
  395. Non-Insulin Medications for the Treatment of Diabetes
  396. Acute Complications of Poor Glycemic Control
  397. Glucagon for Treatment of Severe Hypoglycemia
  398. Summary of Major Nursing Implications
  399. Chapter 58 Drugs for Thyroid Disorders
  400. Thyroid Physiology
  401. Thyroid Function Tests
  402. Thyroid Pathophysiology
  403. Thyroid Hormone Preparations for Hypothyroidism
  404. Drugs for Hyperthyroidism
  405. Key Points
  406. Summary of Major Nursing Implications
  407. Chapter 59 Drugs Related to Hypothalamic and Pituitary Function
  408. Overview of Hypothalamic and Pituitary Endocrinology
  409. Growth Hormone
  410. Mecasermin (Insulin-Like Growth Factor-1)
  411. Prolactin
  412. Antidiuretic Hormone (Vasopressin)
  413. Antidiuretic Hormone (Vasopressin) Antagonists
  414. Drugs for Acromegaly
  415. Key Points
  416. Summary of Major Nursing Implications
  417. Chapter 60 Drugs for Disorders of the Adrenal Cortex
  418. Physiology of the Adrenocortical Hormones
  419. Pathophysiology of the Adrenocortical Hormones
  420. Agents for Replacement Therapy in Adrenocortical Insufficiency
  421. Agents for Diagnosing Adrenocortical Disorders
  422. Key Points
  423. Summary of Major Nursing Implications
  424. Unit IX Women’s Health
  425. Chapter 61 Estrogens and Progestins
  426. The Menstrual Cycle
  427. Estrogens
  428. Selective Estrogen Receptor Modulators (SERMs)
  429. Progestins
  430. Menopausal Hormone Therapy
  431. Key Points
  432. Summary of Major Nursing Implications
  433. Chapter 62 Birth Control
  434. Effectiveness of Birth Control Methods
  435. Selecting a Birth Control Method
  436. Oral Contraceptives
  437. Combination Contraceptives With Novel Delivery Systems
  438. Long-Acting Contraceptives
  439. Spermicides
  440. Barrier Devices
  441. Drugs for Medical Abortion
  442. Key Points
  443. Summary of Major Nursing Implications
  444. Chapter 63 Drug Therapy for Infertility
  445. Infertility: Causes and Treatment Strategies
  446. Drugs Used to Treat Female Infertility
  447. Key Points
  448. Summary of Major Nursing Implications
  449. Chapter 64 Drugs That Affect Uterine Function
  450. Drugs for Preterm Labor
  451. Drugs for Cervical Ripening and Induction of Labor
  452. Drugs for Postpartum Hemorrhage
  453. Drugs for Menorrhagia
  454. Summary of Major Nursing Implications
  455. Unit X Men’s Health
  456. Chapter 65 Androgens
  457. Testosterone
  458. Clinical Pharmacology of the Androgens
  459. Androgen Preparations for Male Hypogonadism
  460. Androgen (Anabolic Steroid) Abuse by Athletes
  461. Key Points
  462. Summary of Major Nursing Implications
  463. Chapter 66 Drugs for Erectile Dysfunction and Benign Prostatic Hyperplasia
  464. Erectile Dysfunction
  465. Benign Prostatic Hyperplasia
  466. Summary of Major Nursing Implications
  467. Unit XI Anti-Inflammatory, Antiallergic, and Immunologic Drugs
  468. Chapter 67 Review of the Immune System
  469. Introduction to the Immune System
  470. Antibody-Mediated (Humoral) Immunity
  471. Cell-Mediated Immunity
  472. Key Points
  473. Chapter 68 Childhood Immunization
  474. General Considerations
  475. Target Diseases
  476. Specific Vaccines and Toxoids
  477. Key Points
  478. Chapter 69 Immunosuppressants
  479. Calcineurin Inhibitors
  480. mTOR Inhibitors
  481. Glucocorticoids
  482. Cytotoxic Drugs
  483. Antibodies
  484. Key Points
  485. Summary of Major Nursing Implications
  486. Chapter 70 Antihistamines
  487. Histamine
  488. The Two Types of Antihistamines: H1 Antagonists and H2 Antagonists
  489. Histamine1 Antagonists I: Basic Pharmacology
  490. Histamine1 Antagonists Ii: Preparations
  491. Key Points
  492. Summary of Major Nursing Implications
  493. Chapter 71 Cyclooxygenase Inhibitors
  494. Mechanism of Action
  495. Classification of Cyclooxygenase Inhibitors
  496. First-Generation NSAIDs
  497. Second-Generation NSAIDs (COX-2 Inhibitors, Coxibs)
  498. Acetaminophen
  499. AHA Statement on the use of COX Inhibitors for Chronic Pain
  500. Key Points
  501. Summary of Major Nursing Implications
  502. Chapter 72 Glucocorticoids in Nonendocrine Disorders
  503. Review of Glucocorticoid Physiology
  504. Pharmacology of the Glucocorticoids
  505. Key Points
  506. Summary of Major Nursing Implications
  507. Unit XII Drugs for Bone and Joint Disorders
  508. Chapter 73 Drug Therapy for Rheumatoid Arthritis
  509. Pathophysiology of Rheumatoid Arthritis
  510. Overview of Therapy
  511. Nonsteroidal Anti-Inflammatory Drugs
  512. Glucocorticoids
  513. Nonbiologic (Traditional) Disease-Modifying Antirheumatic Drugs
  514. Biologic Disease-Modifying Antirheumatic Drugs
  515. Key Points
  516. Summary of Major Nursing Implications
  517. Chapter 74 Drug Therapy for Gout
  518. Pathophysiology of Gout
  519. Overview of Drug Therapy
  520. Drugs for Acute Gouty Arthritis
  521. Drugs for Hyperuricemia (Urate-Lowering Therapy)
  522. Key Points
  523. Chapter 75 Drugs Affecting Calcium Levels and Bone Mineralization
  524. Calcium Physiology
  525. Calcium-Related Pathophysiology
  526. Drugs for Disorders Involving Calcium and Bone Mineralization
  527. Osteoporosis
  528. Key Points
  529. Summary of Major Nursing Implications
  530. Unit XIII Respiratory Tract Drugs
  531. Chapter 76 Drugs for Asthma and Chronic Obstructive Pulmonary Disease
  532. Basic Considerations
  533. Anti-Inflammatory Drugs
  534. Bronchodilators
  535. Glucocorticoid–Long-Acting Beta2-Agonist Combinations
  536. Beta2-Adrenergic Agonist–Anticholinergic Combinations
  537. Management of Asthma
  538. Management of COPD
  539. Summary of Major Nursing Implications
  540. Chapter 77 Drugs for Allergic Rhinitis, Cough, and Colds
  541. Drugs for Allergic Rhinitis
  542. Drugs for Cough
  543. Cold Remedies: Combination Preparations
  544. Key Points
  545. Unit XIV Gastrointestinal Drugs
  546. Chapter 78 Drugs for Peptic Ulcer Disease
  547. Pathogenesis of Peptic Ulcers
  548. Overview of Treatment
  549. Antibacterial Drugs
  550. Histamine2 Receptor Antagonists
  551. Proton Pump Inhibitors
  552. Other Antiulcer Drugs
  553. Key Points
  554. Summary of Major Nursing Implications
  555. Chapter 79 Laxatives
  556. General Considerations
  557. Basic Pharmacology of Laxatives
  558. Laxative Abuse
  559. Key Points
  560. Summary of Major Nursing Implications
  561. Chapter 80 Other Gastrointestinal Drugs
  562. Antiemetics
  563. Drugs for Motion Sickness
  564. Antidiarrheal Agents
  565. Drugs for Irritable Bowel Syndrome
  566. Drugs for Inflammatory Bowel Disease
  567. Prokinetic Agents
  568. Palifermin
  569. Pancreatic Enzymes
  570. Drugs Used to Dissolve Gallstones
  571. Anorectal Preparations
  572. Key Points
  573. Unit XV Nutrition
  574. Chapter 81 Vitamins
  575. Basic Considerations
  576. Fat-Soluble Vitamins
  577. Water-Soluble Vitamins
  578. Key Points
  579. Chapter 82 Drugs for Weight Loss
  580. Assessment of Weight-Related Health Risk
  581. Overview of Obesity Treatment
  582. Weight-Loss Drugs
  583. A Note Regarding Drugs for Weight Loss
  584. Key Points
  585. Unit XVI Chemotherapy of Infectious Diseases
  586. Chapter 83 Basic Principles of Antimicrobial Therapy
  587. Selective Toxicity
  588. Classification of Antimicrobial Drugs
  589. Acquired Resistance to Antimicrobial Drugs
  590. Selection of Antibiotics
  591. Host Factors That Modify Drug Choice, Route of Administration, or Dosage
  592. Dosage and Duration of Treatment
  593. Therapy With Antibiotic Combinations
  594. Prophylactic Use of Antimicrobial Drugs
  595. Misuses of Antimicrobial Drugs
  596. Monitoring Antimicrobial Therapy
  597. Key Points
  598. Chapter 84 Drugs That Weaken the Bacterial Cell Wall I
  599. Introduction to the Penicillins
  600. Properties of Individual Penicillins
  601. Key Points
  602. Summary of Major Nursing Implications
  603. Chapter 85 Drugs That Weaken the Bacterial Cell Wall II
  604. Cephalosporins
  605. Carbapenems
  606. Other Inhibitors of Cell Wall Synthesis
  607. Key Points
  608. Summary of Major Nursing Implications
  609. Chapter 86 Bacteriostatic Inhibitors of Protein Synthesis
  610. Tetracyclines
  611. Macrolides
  612. Other Bacteriostatic Inhibitors of Protein Synthesis
  613. Key Points
  614. Summary of Major Nursing Implications
  615. Chapter 87 Aminoglycosides
  616. Basic Pharmacology of the Aminoglycosides
  617. Properties of Individual Aminoglycosides
  618. Key Points
  619. Summary of Major Nursing Implications
  620. Chapter 88 Sulfonamides and Trimethoprim
  621. Sulfonamides
  622. Trimethoprim
  623. Trimethoprim/Sulfamethoxazole
  624. Key Points
  625. Summary of Major Nursing Implications
  626. Chapter 89 Drug Therapy for Urinary Tract Infections
  627. Organisms That Cause Urinary Tract Infections
  628. Specific Urinary Tract Infections and Their Treatment
  629. Urinary Tract Antiseptics
  630. Key Points
  631. Chapter 90 Antimycobacterial Agents
  632. Drugs for Tuberculosis
  633. Drugs for Leprosy (Hansen’s Disease)
  634. Drugs for Mycobacterium avium Complex Infection
  635. Summary of Major Nursing Implications
  636. Chapter 91 Miscellaneous Antibacterial Drugs
  637. Fluoroquinolones
  638. Additional Antibacterial Drugs
  639. Key Points
  640. Summary of Major Nursing Implications
  641. Chapter 92 Antifungal Agents
  642. Drugs for Systemic Mycoses
  643. Drugs for Superficial Mycoses
  644. Key Points
  645. Summary of Major Nursing Implications
  646. Chapter 93 Antiviral Agents I
  647. Drugs for Infection With Herpes Simplex Viruses and Varicella-Zoster Virus
  648. Drugs for Cytomegalovirus Infection
  649. Drugs for Hepatitis
  650. Drugs for Influenza
  651. Drugs for Respiratory Syncytial Virus Infection
  652. Summary of Major Nursing Implications
  653. Chapter 94 Antiviral Agents II
  654. Pathophysiology
  655. Classification of Antiretroviral Drugs
  656. Drug Interactions
  657. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
  658. Non-Nucleoside Reverse Transcriptase Inhibitors
  659. Protease Inhibitors
  660. Integrase Strand Transfer Inhibitors
  661. HIV Fusion Inhibitors
  662. CCR5 Antagonists
  663. Management of HIV Infection
  664. Preventing HIV Infection With Drugs
  665. Prophylaxis and Treatment of Opportunistic Infections
  666. HIV Vaccines
  667. Keeping Current
  668. Key Points
  669. Summary of Major Nursing Implications
  670. Chapter 95 Drug Therapy for Sexually Transmitted Infections
  671. Chlamydia trachomatis Infections
  672. Gonococcal Infections
  673. Nongonococcal Urethritis
  674. Pelvic Inflammatory Disease
  675. Acute Epididymitis
  676. Syphilis
  677. Acquired Immunodeficiency Syndrome
  678. Bacterial Vaginosis
  679. Trichomoniasis
  680. Chancroid
  681. Herpes Simplex Virus Infections
  682. Proctitis
  683. Venereal Warts
  684. Making Sense of Treatment
  685. Key Points
  686. Chapter 96 Antiseptics and Disinfectants
  687. General Considerations
  688. Properties of Individual Antiseptics and Disinfectants
  689. Hand Hygiene for Healthcare Workers
  690. Key Points
  691. Unit XVII Chemotherapy of Parasitic Diseases
  692. Chapter 97 Anthelmintics
  693. Classification of Parasitic Worms
  694. Helminthic Infestations
  695. Drugs of Choice for Helminthiasis
  696. Key Points
  697. Chapter 98 Antiprotozoal Drugs I
  698. Life Cycle of the Malaria Parasite
  699. Types of Malaria
  700. Principles of Antimalarial Therapy
  701. Pharmacology of the Major Antimalarial Drugs
  702. Key Points
  703. Chapter 99 Antiprotozoal Drugs II
  704. Protozoal Infections
  705. Drugs of Choice for Protozoal Infections
  706. Key Points
  707. Chapter 100 Ectoparasiticides
  708. Ectoparasitic Infestations
  709. Pharmacology of Ectoparasiticides
  710. Key Points
  711. Unit XVIII Cancer Chemotherapy
  712. Chapter 101 Basic Principles of Cancer Chemotherapy
  713. What Is Cancer?
  714. The Growth Fraction and Its Relationship to Chemotherapy
  715. Obstacles to Successful Chemotherapy
  716. Strategies for Achieving Maximum Benefits From Chemotherapy
  717. Major Toxicities of Chemotherapeutic Drugs
  718. Making the Decision to Treat
  719. Looking Ahead
  720. Key Points
  721. Chapter 102 Anticancer Drugs I
  722. Introduction to the Cytotoxic Anticancer Drugs
  723. Alkylating Agents
  724. Platinum Compounds
  725. Antimetabolites
  726. Hypomethylating Agents
  727. Antitumor Antibiotics
  728. Mitotic Inhibitors
  729. Topoisomerase Inhibitors
  730. Miscellaneous Cytotoxic Drugs
  731. Key Points
  732. Chapter 103 Anticancer Drugs II
  733. Drugs for Breast Cancer
  734. Drugs for Prostate Cancer
  735. Targeted Anticancer Drugs
  736. Immunostimulants
  737. Other Noncytotoxic Anticancer Drugs
  738. Unit XIX Miscellaneous Drugs and Therapies
  739. Chapter 104 Drugs for the Eye
  740. Drugs for Glaucoma
  741. Cycloplegics and Mydriatics
  742. Drugs for Allergic Conjunctivitis
  743. Drugs for Age-Related Macular Degeneration
  744. Additional Ophthalmic Drugs
  745. Key Points
  746. Chapter 105 Drugs for the Skin
  747. Anatomy of the Skin
  748. Topical Drug Formulations
  749. Topical Glucocorticoids
  750. Keratolytic Agents
  751. Acne
  752. Drugs for Rosacea
  753. Sunscreens
  754. Psoriasis
  755. Drugs for Actinic Keratoses
  756. Drugs for Atopic Dermatitis (Eczema)
  757. Agents Used to Remove Warts
  758. Drugs for Nonsurgical Cosmetic Procedures
  759. Antiperspirants and Deodorants
  760. Drugs for Seborrheic Dermatitis and Dandruff
  761. Drugs for Hair Loss
  762. Eflornithine for Unwanted Facial Hair
  763. Drugs for Impetigo
  764. Local Anesthetics
  765. Key Points
  766. Chapter 106 Drugs for the Ear
  767. Anatomy of the Ear
  768. Otitis Media and Its Management
  769. Otitis Externa and Its Management
  770. Key Points
  771. Summary of Major Nursing Implications
  772. Chapter 107 Additional Noteworthy Drugs
  773. Drugs for Pulmonary Arterial Hypertension
  774. Drugs for Neonatal Respiratory Distress Syndrome
  775. Drugs for Cystic Fibrosis
  776. Drugs for Sickle Cell Anemia
  777. Phosphate Binders for Patients on Dialysis
  778. Gamma-Hydroxybutyrate for Cataplexy in Patients With Narcolepsy
  779. Riluzole for Amyotrophic Lateral Sclerosis
  780. Tetrabenazine for Chorea of Huntington’s Disease
  781. Drugs for Fibromyalgia
  782. Drugs for Hereditary Angioedema
  783. Belimumab for Systemic Lupus Erythematosus
  784. Key Points
  785. Chapter 108 Complementary and Alternative Therapy
  786. Regulation of Dietary Supplements
  787. Private Quality Certification Programs
  788. Standardization of Herbal Products
  789. Adverse Interactions With Conventional Drugs
  790. Some Commonly Used Dietary Supplements
  791. Harmful Supplements to Avoid
  792. Key Points
  793. Unit XX Toxicology
  794. Chapter 109 Management of Poisoning
  795. Fundamentals of Treatment
  796. Drugs and Procedures Used to Minimize Poison Absorption
  797. Drugs and Procedures Used for Poison Removal
  798. Specific Antidotes
  799. Poison Control Centers
  800. Key Points
  801. Chapter 110 Potential Weapons of Biologic, Radiologic, and Chemical Terrorism
  802. Bacteria and Viruses
  803. Biotoxins
  804. Chemical Weapons
  805. Radiologic Weapons
  806. Key Points
  807. Appendix A Canadian Drug Information*
  808. Canadian Drug Legislation
  809. Drug Advertising
  810. International System of Units
  811. Drug Serum Concentrations
  812. Further Reading
  813. Appendix B Prototype Drugs and Their Major Uses
  814. Peripheral Nervous System Drugs
  815. Central Nervous System Drugs
  816. Diuretics
  817. Drugs That Affect the Heart, Blood Vessels, and Blood
  818. Drugs for Endocrine Disorders
  819. Women’s Health
  820. Men’s Health
  821. Anti-Inflammatory, Antiallergic, and Immunologic Drugs
  822. Drugs for Bone and Joint Disorders
  823. Respiratory Tract Drugs
  824. Gastrointestinal Drugs
  825. Drugs for Weight Loss
  826. Drugs for Bacterial Infections
  827. Drugs for Fungal Infections
  828. Drugs for Viral Infections
  829. Drugs for Parasitic Diseases
  830. Anticancer Drugs: Cytoxic Agents
  831. Anticancer Drugs: Hormonal Agents, Targeted Drugs, and Other Noncytotoxic Anticancer Drugs
  832. Other Important Drugs
  833. Index
  834. Special Interest Topics